Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice

  • Agents Actions. 1993 May;39(1-2):42-8. doi: 10.1007/BF01975713.
Y Fujimori  1 ,  T Nakamura ,  K Shimizu ,  T Yamamuro ,  K Wanaka ,  S Okamoto ,  Y Katsuura
Affiliations
  • 1. Department of Orthopaedic Surgery, Faculty of Medicine, Kyoto University, Japan.
PMID: 8285139 DOI: 10.1007/BF01975713
Abstract

A study was conducted to evaluate the effects of a new, highly selective plasma Kallikrein Inhibitor, PKSI-527, on collagen-induced arthritis (CIA) in mice. PKSI-527 or indomethacin was administered daily intraperitoneally from day 20 postimmunization. Clinical evaluation was performed, and two of the components of the kallikrein-kinin system, high-molecular-weight (HMW) kininogen and plasma prekallikrein, were assayed. PKSI-527, as well as indomethacin, reduced the severity of arthritis significantly. PKSI-527, but not indomethacin, restored consumed components of the kallikrein-kinin system. These results suggest that PKSI-527 suppresses CIA by modifying the kallikrein-kinin system and PKSI-527 as a synthetic plasma Kallikrein Inhibitor would be a valuable tool to study the mechanism of inflammation of arthritic diseases.

Products